# Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19

> **NCT05094596** · PHASE4 · UNKNOWN · sponsor: **Bugra Kerget** · enrollment: 180 (estimated)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Standart treatment group
- **DRUG:** Montelukast sodium 10 mg treatment
- **DRUG:** Montelukast sodium 20 mg treatment

## Key facts

- **NCT ID:** NCT05094596
- **Lead sponsor:** Bugra Kerget
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-22
- **Primary completion:** 2021-12-22
- **Final completion:** 2022-01-22
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2021-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094596, "Effect of Montelukast Therapy on Clinical Course, Pulmonary Function, and Mortality in Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05094596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*